Evaluation of a nomogram used to predict the pathologic stage of clinically localized prostate carcinoma

Cancer

Volumn 79, Issue 3, 1997, Pages 528-537

  Kattan, Michael W ^a   Stapleton, Alan M F ^a   Wheeler, Thomas M ^a,b   Scardino, Peter T ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

clinical prognostic factors; pathologic stage; prognosis; prostate carcinoma; prostate specific antigen; regression analysis; statistics; tumor grade

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; DIAGNOSTIC ACCURACY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NOMOGRAM; PRIORITY JOURNAL; PROSTATE CARCINOMA;

DATA INTERPRETATION, STATISTICAL; HUMANS; MALE; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 0031016543     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19970201)79:3<528::AID-CNCR15>3.0.CO;2-5     Document Type: Article

References (44)

1. Parker SL, Tong T, Bolden S, Wingo PA. Cancer Statistics, 1996. CA Cancer J Clin 1996;46:5-27.
2. Stamey TA, Freiha FS, McNeal JE, Redwine EA, Whittemore AS, Schmid HP. Localized prostate cancer: relationship of tumor volume to clinical significance for treatment of prostate cancer. Cancer 1993;71:933-8.
3. Catalona WJ. Surgical management of prostate cancer: contemporary results with anatomic radical prostatectomy. Cancer 1995;75:1903-8.
4. Eastham JA, Scardino PT. Radical Prostatectomy. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED. Campbell's Urology. 7th edition. Philadelphia: WB Saunders Co. In press.
5. Partin AW, Yoo J, Carter HB, Pearson JD, Chan DW, Epstein JI, et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 1993;150:110-4.
6. Epstein JI, Carmichael M, Partin AW, Walsh PC. Is tumor volume an independent predictor of progression following radical prostatectomy? A multivariate analysis of 185 clinical stage B adenocarcinomas of the prostate with 5 years of followup. J Urol 1993;149:1478-81.
7. Epstein JI, Carmichael MJ, Pizov G, Walsh PC. Influence of capsular penetration on progression following radical prostatectomy: a study of 196 cases with long-term followup. J Urol 1993;150:135-41.
8. Epstein JI, Pizov G, Walsh PC. Correlation of pathologic findings with progression after radical retropubic prostatectomy. Cancer 1993;71:3582-93.
9. Epstein JI, Carmichael M, Walsh PC. Adenocarcinoma of the prostate invading the seminal vesicle: definition and relation of tumor volume, grade and margins of resection to prognosis. J Urol 1993;149:1040-5.
10. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, Pavone-Macaluso M. The TNM classification of prostate cancer. Prostate 1992;4:129-38.
11. Wheeler TM. Anatomic considerations in carcinoma of the prostate. Urol Clin North Am 1989;16:623-34.
12. Cleveland WS. Robust locally weighted regression and smoothing scatterplots. J Amer Stat Assoc 1979;74:829-36.
13. Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15:361-87.
14. Harrell FE, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of medical tests. JAMA 1982;247:2543-6.
15. Harrell FE. Design: S-Plus function for biostatistical/epidemiologic modeling, testing, estimation, validation, graphics, prediction, and typesetting by storing enhanced model design attributes in the fit. 1994. Programs available from statlib@lib.stat.cmu.edu.
16. Ritter MA, Messing EM, Shanahan TG, Potts S, Chappell RT, Kinsella TJ. Prostate-specific antigen as a predictor of radiotherapy response and patterns of failure in localized prostate cancer. J Clin Oncol 1992;10:1208-17.
17. Zagars GK, von Eschenbach AC, Ayala AG. Prognostic factors in prostate cancer: analysis of 874 patients treated with radiation therapy. Cancer 1993;72:1709-25.
18. Zietman AL, Shipley WU, Coen JJ. Radical prostatectomy and radical radiation therapy for clinical stages T1 to T2 adenocarcinoma of the prostate: new insights into outcome from repeat biopsy and prostate specific antigen followup. J Urol 1994;152:1806-12.
19. Pisansky TM, Cha SS, Earle JD, Durr ED, Kozelsky TF, Wieand S, Oesterling JE. Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 1993;11:2158-66.
20. Frazier HA, Robertson JE, Humphrey PA, Paulson DF. Is prostate specific antigen of clinical importance in evaluating outcome after radical prostatectomy? J Urol 1993;149:516-8.
21. Partin AW, Pound CR, Clemens JQ, Epstein JI, Walsh PC. Serum PSA after anatomic radical prostatectomy. Urol Clin North Am 1993;20:713-25.
22. Ravery V, Boccon-Gibod LA, Dauge-Geffroy MC, Billebaud T, Delmas V, Meulemans A, Toublanc M, Boccon-Gibod L. Systematic biopsies accurately predict extracapsular extension of prostate cancer and persistent/recurrent detectable PSA after radical prostatectomy. Urology 1994;44:371-6.
23. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, Wein A. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-8.
24. Schelhammer PF, El-Mahdi AM, Wright GL, Kolm P, Ragle R. Prostate-specific antigen to determine progression-free survival after radiation therapy for localized carcinoma of prostate. Urology 1993;42:13-20.
25. Kaplan ID, Cox RS, Bagshaw MA. Prostate specific antigen after external beam radiotherapy for prostatic cancer: followup. J Urol 1993;149:519-22.
26. Scardino PT, Shinohara K, Wheeler TM, Carter SStC. Staging of prostate cancer: value of ultrasonography. Urol Clin North Am 1989;16:713-34.
27. Kojima M, Troncoso P, Babaian, RJ. Use of prostate-specific antigen and tumor volume in predicting needle biopsy grading error. Urology 1995;45:807-12.
28. Garnett JE, Oyasu R, Grayhack JT. The accuracy of diagnostic biopsy specimens in predicting tumor grades by Gleason's classification of radical prostatectomy specimens. J Urol 1984;131:690-3.
29. Mills SE, Fowler JE Jr. Gleason histologic grading of prostatic carcinoma: correlations between biopsy prostatectomy specimens. Cancer 1986;57:346-9.
30. Humphrey PA, Baty J, Keetch D. Relationship between serum prostate specific antigen, needle biopsy findings, and histopathologic features of prostatic carcinoma in radical prostatectomy tissues. Cancer 1995;75:1842-9.
31. Narayan P, Viswanathan G, Taylor SP, Tewari A, Presti JC Jr, Leidich R, et al. The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. Urology 1995;46:205-12.
32. Hanks GE, Lee WR, Schultheiss TE. Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 1995;154:456-9.
33. Kabalin JN, McNeal JE, Johnstone IM, Stamey TA. Serum prostate-specific antigen and the biologic progression of prostate cancer. Urology 1995;46:65-70.
34. Reynard JM, Peters TJ, Gillatt D. Prostate-specific antigen and prognosis in patients with metastatic prostate cancer: a multivariable analysis of prostate cancer mortality. Br J Urol 1995;75:507-15.
35. D'Amico AV, Whittington R, Malkowicz SB, Schultz D, Schnall M, Tomaszewski JE, et al. A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. J Urol 1995;154:131-8.
36. Norberg M, Holmberg L, Wheeler T, Magnusson A. Five year follow-up after radical prostatectomy for localized prostate cancer: a study of the impact of different tumor variables on progression. Scand J Urol Nephrol 1994;28:391-9.
37. Zagars GK, Pollack A. Radiation therapy for T1 and T2 prostate cancer: prostate-specific antigen and disease outcome. Urology 1995;45:476-83.
38. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone: serum prostate-specific antigen-driven outcome analysis. J Clin Oncol 1995;13:464-9.
39. Zagars GK. Prostate specific antigen as an outcome variable for T1 and T2 prostate cancer treated by radiation therapy. J Urol 1994;152:1786-91.
40. Smith DS, Catalona WJ. Rate of change in serum prostate specific antigen levels as a method for prostate cancer detection. J Urol 1994;152:1163-7.
41. Zietman AL, Coen JJ, Shipley WU, Willett CG, Efird JT. Radical radiation therapy in the management of prostatic adenocarcinoma: the initial prostate specific antigen value as a predictor of treatment outcome. J Urol 1994;151:640-5.
42. Freeman JA, Esrig D, Grossfeld GD, Stein JP, Chen S-C, Young LL, et al. Incidence of occult lymph node metastases in pathological stage (pT3N0) prostate cancer. J Urol 1995;154:474-8.
43. Epstein JI, Partin AW, Sauvageot J, Walsh PC. Prediction of progression following radical prostatectomy: a multivariate analysis of 721 men with long-term follow-up. Am J Surg Pathol 1996;20:286-92.
44. Ohori M, Wheeler TM, Kattan MW, Goto Y, Scardino PT. Prognostic significance of positive surgical margins in radical prostatectomy specimens. J Urol 1995;154:1818-24.